Datasets:
nzindoc
/
dataset-multiple-myeloma-study-dictionary

Dataset card Viewer Files Community
instruction
stringclasses
1 value
input
stringlengths
104
436
output
stringlengths
45
55
text
stringlengths
247
577
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Phase 3 ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Anti-CD38 MAb, Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Velcade (Bortezomib) +Melphalan+Prednisone (VMP), Anti-CD38 MAb ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479
Identify the study with the following condition.
Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
Popular Name is ALCYONE, Study ID is NCT02195479
### Instruction: Identify the study with the following condition. ### Input: Newly Diagnosed Multiple Myeloma (NDMM), Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Phase 3, Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) ### Output: Popular Name is ALCYONE, Study ID is NCT02195479